Argent Biopharma (AU:RGT) has released an update.
Argent BioPharma Limited has announced the issuance of 2.5 million new shares, which are exempt from the usual restrictions on sales thanks to a notice under Section 708A(5) of the Corporations Act 2001. The company confirms compliance with all necessary provisions and declares that there is no undisclosed information that would affect an investor’s assessment of the shares’ value. Argent BioPharma is an innovative biopharmaceutical company focusing on nanotechnology and multi-target therapies for CNS and immunology.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.
